CMVIG Prophylaxis in Belatacept Conversion Kidney Transplant Recipients

NCT07096453

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	University of Minnesota
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (4)

- Adult (18-70 year old) kidney transplant recipients
- Patients transitioning from conventional CNI-based immunosuppression to co-stimulatory blockade (belatacept) immunosuppression OR patients who are stable on belatacept immunosuppression at the time of initial CYTOGAM infusion
- CMV Ig Seronegative Recipient who received a CMV Ig seropositive Donor
- EBV IgG Positive

Exclusion (5)

- Pregnant people
- Subjects unwilling to sign consent and complete follow up visits
- Subjects with IgA immunodeficiency
- Subjects who are receiving IgG therapy or who have received IgG therapy within two months of study enrollment
- Patients who do not speak English and would need a translator and translated consent materials in order to obtain informed consent

Locations (1 total)

University of Minnesota, Minneapolis, Minnesota, United States

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at ClinicalTrials.gov. Generated by ClinicalTrialsFinder.org.